详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting

53| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Dept Med Oncol, Canc Ctr,State Key Lab Oncol South China,Guangdong, Guangzhou 510060, Peoples R China [2]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sr Ward & Phase Clin Trial Ward 1, Dept Med Oncol,Sichuan Canc Ctr,Sch Med, Chengdu 610000, Sichuan, Peoples R China [3]Guangzhou Med Univ, Affiliated Hosp 1, Dept Dermatol, Guangzhou 510120, Guangdong, Peoples R China

出处：

DOI：

ISSN：

关键词： Peripheral T-cell lymphoma Relapse Refractory Clinical research

摘要：

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological malignancies with poor survival, while treatment options for relapsed or refractory (R/R) disease remain quite limited, with a median progression-free survival of only 3-4 months. Notably, the emergence of innovative therapeutic agents and regimens holds promise for durable responses and improved survival for patients with R/R PTCL. We summarize recent advances in the treatment of R/R PTCL from the 2023 ASH Annual Meeting, highlighting novel agents targeting EZH1/2, JAK1, PI3K, KIR3DL2, CD38/CD3xCD28, or CDK9, as well as therapeutic regimens in combination with stem cell transplantation, immunomodulators, epigenetic modifying agents, or CD30/CD16A bispecific antibodies.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 1 区医学

小类 | 2 区血液学 2 区肿瘤学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 HEMATOLOGY Q1 ONCOLOGY

影响因子： 9.4 最新[2023版] 8.3 最新五年平均 9.4 出版当年[2023版] 0 出版当年五年平均 9.4 出版前一年[2023版]

第一作者：

第一作者机构： [1]Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Dept Med Oncol, Canc Ctr,State Key Lab Oncol South China,Guangdong, Guangzhou 510060, Peoples R China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China [2]Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China [3]Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase 1 study [4]A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China [5]Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study [6]Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). [7]A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma [8]Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified [9]Use of Complete Blood Count for Prognostic Evaluation of Peripheral T-Cell Lymphoma [10]Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)